Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
SAN DIEGO—Kihara James, the Principal Accounting Officer at Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), recently reported a series of stock transactions. The company, currently valued at $3.2 billion, has maintained strong financial health with an "GREAT" rating according to InvestingPro analysis. According to a Form 4 filed with the Securities and Exchange Commission, James sold 475 shares of common stock on February 24, 2025, at a price of $19.96 per share, totaling approximately $9,481. The transaction occurred near the stock’s current trading level of $19.01, with the shares showing a 19% gain over the past six months.
The transactions also included the acquisition of 840 shares on February 23, 2025, through the exercise of restricted stock units. These shares were acquired at no cost, as each restricted stock unit represents a contingent right to receive one share of the company’s common stock.
The sales were reportedly made to cover withholding taxes and tax-related items in connection with the vesting of restricted stock units. Following these transactions, James holds 20,228 shares of Acadia Pharmaceuticals.
In other recent news, Acadia Pharmaceuticals has made significant strides with its financial and strategic initiatives. The company recently completed the sale of a Rare Pediatric Disease Priority Review Voucher, earning $150 million, a portion of which is shared with Neuren Pharmaceuticals. Additionally, Acadia has submitted a Marketing Authorization Application to the European Medicines Agency for trofinetide, aiming to treat Rett syndrome, based on positive Phase 3 study results. This move could mark trofinetide as the first approved therapy for Rett syndrome in the European Union.
In terms of strategic development, Acadia has entered an exclusive worldwide licensing agreement with Saniona for SAN711, a potential treatment for essential tremor. This agreement involves an upfront payment of $28 million, with additional milestone payments possible, reflecting Acadia’s commitment to expanding its treatment portfolio. Deutsche Bank (ETR:DBKGn) has initiated coverage on Acadia with a Hold rating, noting the arrival of a new CEO and uncertainties regarding the long-term market penetration of Daybue.
Meanwhile, Baird has reiterated its Outperform rating on Acadia, highlighting the strategic addition of SAN711 to the company’s pipeline. These recent developments showcase Acadia’s ongoing efforts in both financial management and the expansion of its therapeutic offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.